Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.64 |
| ▸ | DDB1 | Q16531 | 18/20 | 0.64 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.54 |
| ▸ | GSPT1 | P15170 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21069262 | 0.92 | CRBN (0.63) | CRBNDDB1IKZF2GSPT1 | |
| SCHEMBL21760140 | 0.85 | IKZF2 (0.59) | CRBNDDB1IKZF2GSPT1 | |
| SCHEMBL29167310 | 0.85 | CRBN (0.63) | CRBNDDB1IKZF2GSPT1 | |
| SCHEMBL31254134 | 0.84 | CRBN (0.65) | CRBNDDB1IKZF2GSPT1 | |
| SCHEMBL25035052 | 0.84 | CRBN (0.57) | CRBNDDB1IKZF2 | |
| SCHEMBL21107817 | 0.83 | CRBN (0.69) | CRBNDDB1IKZF2GSPT1 | |
| SCHEMBL24420973 | 0.83 | CRBN (0.71) | CRBNDDB1IKZF2GSPT1 | |
| SCHEMBL30805411 | 0.83 | CRBN (0.66) | CRBNDDB1IKZF2GSPT1 | |
| SCHEMBL29614567 | 0.83 | CRBN (0.71) | CRBNDDB1IKZF2GSPT1 | |
| SCHEMBL20325482 | 0.83 | DDB1 (0.73) | CRBNDDB1GSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736882-A2 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | Cullgen (Shanghai), Inc. (CN) | 2026-05-06 | — | — | EP | disclosed |
| EP-3841098-B1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-20250388587-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2025-12-25 | — | — | US | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12168057-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240400570-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2024-12-05 | — | — | US | disclosed |
| US-12065442-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | CULLGEN (SHANGHAI), INC. (CN) | 2024-08-20 | — | — | US | disclosed |
| US-20210363146-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2021-11-25 | — | — | US | disclosed |
| US-20210315999-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2021-10-14 | — | — | US | disclosed |
| EP-3841098-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | Cullgen (Shanghai), Inc. (CN) | 2021-06-30 | — | — | EP | disclosed |
| CN-112888681-A | Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2021-06-01 | — | — | CN | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| EP-3731869-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| WO-2020038415-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2020-02-27 | — | — | WO | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874743-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885IKZF2 361/4885 |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885IKZF2 361/4885 |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885IKZF2 361/4885 |
| US-20250388587-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | ERBB2, MUSK, ERBB3 | CRBN 149/4885DDB1 1222/4885IKZF2 2290/4885 |
| US-20240400570-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | CRBN 330/4885DDB1 480/4885IKZF2 2170/4885 |
| US-12168057-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885IKZF2 361/4885 |
| US-12065442-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | MUSK, NTRK1, ERBB2 | CRBN 194/4885DDB1 418/4885IKZF2 1536/4885 |
| US-20210363146-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, NTRK1, ERBB2 | CRBN 194/4885DDB1 418/4885IKZF2 1536/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885IKZF2 361/4885 |
| US-20210315999-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | CRBN 330/4885DDB1 480/4885IKZF2 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.